| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.5 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | -0.023 | 0.5 |